About Psyence Biomedical Ltd. Warrant
https://www.psyencebiomed.comPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
CEO
Jody Aufrichtig
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Full time employees 0
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $1404
52w High $0.02
52w Low $0.02
P/E 0
Volume 2.15K
Outstanding Shares 71.27K
About Psyence Biomedical Ltd. Warrant
https://www.psyencebiomed.comPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2024 | $0 | $1.16M ▲ | $141.47K ▲ | 0% | $0 | $146.2K ▲ |
| Q2-2023 | $0 | $176.16K ▼ | $-314.03K ▼ | 0% | $0 | $-281.75K ▼ |
| Q2-2022 | $0 | $244K | $-244.67K | 0% | $0 | $-244K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2024 | $1.93M ▲ | $2.25M ▲ | $3.51M ▲ | $-1.26M ▼ |
| Q2-2023 | $598.38K | $665.78K | $1.64M | $-977.39K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|
CEO
Jody Aufrichtig
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public N/A
Full time employees 0
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0